The role of liver cancer stem cells in hepatocellular carcinoma metastasis

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–9. doi:10.1016/S0140-6736(18)30010-2.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Longo DL. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62. doi:10.1056/NEJMra1713263.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–17. doi:10.1038/nrgastro.2016.193.
   PubMed Web of Science ®Google Scholar
• Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72(2):262–76. doi:10.1016/j.jhep.2019.11.017.
   PubMed Web of Science ®Google Scholar
• Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg. 2017;266(1):118–25. doi:10.1097/SLA.0000000000001894.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, Castells L, Sandroussi C, Bilbao I, Dopazo C, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American Series. Ann Surg Oncol. 2015;22(7):2286–94. doi:10.1245/s10434-014-4273-6.
   PubMed Web of Science ®Google Scholar
• Castaneda M, den Hollander P, Kuburich NA, Rosen JM, Mani SA. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022;87:17–31. doi:10.1016/j.semcancer.2022.10.006.
   PubMed Web of Science ®Google Scholar
• Ganesh K, Massague J. Targeting metastatic cancer. Nat Med. 2021;27(1):34–44. doi:10.1038/s41591-020-01195-4.
   PubMed Web of Science ®Google Scholar
• Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28. doi:10.1038/s41392-020-0134-x.
   PubMed Web of Science ®Google Scholar
• Massague J, Ganesh K. Metastasis-initiating cells and ecosystems. Cancer Discov. 2021;11(4):971–94. doi:10.1158/2159-8290.CD-21-0010.
   PubMed Web of Science ®Google Scholar
• de Sousae Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z, Koeppen H, et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature. 2017;543(7647):676–680. doi:10.1038/nature21713.
   PubMed Web of Science ®Google Scholar
• Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A. Cancer stem cells: the root of tumor recurrence and metastases. Semin Cancer Biol. 2017;44:10–24. doi:10.1016/j.semcancer.2017.02.011.
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu S, Wang Y, Dai W, Zou H, Wang S, Zhang J, Pan J. Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma. Mol Cancer. 2019;18(1):159. doi:10.1186/s12943-019-1068-1.
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–34. doi:10.1038/nm.4409.
   PubMed Web of Science ®Google Scholar
• Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017;16(1):4. doi:10.1186/s12943-016-0572-9.
   PubMed Web of Science ®Google Scholar
• Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, et al. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics. 2021;11(7):3489–501. doi:10.7150/thno.54648.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lu T, Huang L, Wang Z, Yan Z, Guan Y, Hu W, Fan Z, Zhu P. Circular RNA cia-MAF drives self-renewal and metastasis of liver tumor-initiating cells via transcription factor MAFF. J Clin Invest. 2021;131(19). doi:10.1172/JCI148020.
   Web of Science ®Google Scholar
• Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 2013;57(4):1484–97. doi:10.1002/hep.26168.
   PubMed Web of Science ®Google Scholar
• Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9(1):74. doi:10.1186/s13045-016-0307-9.
   PubMedGoogle Scholar
• Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15. doi:10.1016/j.cell.2008.03.027.
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–29. doi:10.1038/nrclinonc.2017.44.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, Mei C, Yan Y, Jin H, Gao J, et al. ZnAs@SiO2nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. Theranostics. 2019;9(15):4391–4408. doi:10.7150/thno.32462.
   PubMed Web of Science ®Google Scholar
• Chen Z, Xiang L, Li L, Ou H, Fang Y, Xu Y, Liu Q, Hu Z, Huang Y, Li X, et al. TGF-β1 induced deficiency of linc00261 promotes epithelial–mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3. J Transl Med. 2022;20(1):75. doi:10.1186/s12967-022-03276-z.
   PubMed Web of Science ®Google Scholar
• Huan HB, Yang DP, Wen XD, Chen X-J, Zhang L, Wu L-L, Bie P, Xia F. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2017;36(1):86. doi:10.1186/s13046-017-0559-4.
   PubMedGoogle Scholar
• Zhou JN, Zeng Q, Wang HY, Zhang B, Li S-T, Nan X, Cao N, Fu C-J, Yan X-L, Jia Y-L, et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology. 2015;62(3):801–15. doi:10.1002/hep.27887.
   PubMed Web of Science ®Google Scholar
• Ou H, Chen Z, Xiang L, Fang Y, Xu Y, Liu Q, Hu Z, Li X, Huang Y, Yang D, et al. Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. Cancer Sci. 2019;110(4):1169–82. doi:10.1111/cas.13949.
   PubMed Web of Science ®Google Scholar
• Fung SW, Cheung PF, Yip CW, Ng LWC, Cheung TT, Chong CCN, Lee C, Lai PBS, Chan AWH, Tsao GSW, et al. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Lett. 2019;457:98–109. doi:10.1016/j.canlet.2019.05.010.
   PubMed Web of Science ®Google Scholar
• Modi SJ, Kulkarni VM. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): reversal of TGF-beta induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Eur J Med Chem. 2020;207:112851. doi:10.1016/j.ejmech.2020.112851.
   PubMed Web of Science ®Google Scholar
• Fan QM, Jing YY, Yu GF, Kou X-R, Ye F, Gao L, Li R, Zhao Q-D, Yang Y, Lu Z-H, et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial–mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 2014;352(2):160–168. doi:10.1016/j.canlet.2014.05.008.
   PubMed Web of Science ®Google Scholar
• Jing L, Ruan Z, Sun H, Li Q, Han L, Huang L, Yu S, Wang Y, Guo H, Jiao M, et al. Epithelial–mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma. J Cell Physiol. 2019;234(10):18448–18458. doi:10.1002/jcp.28480.
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang BH, Zheng SS, Gao D-M, Qiu S-J, Wu W-Z, Ren Z-G. Coexpression of gene Oct4 and nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. J Hematol Oncol. 2015;8(1):23. doi:10.1186/s13045-015-0119-3.
   PubMedGoogle Scholar
• Nishiyama M, Tsunedomi R, Yoshimura K, Hashimoto N, Matsukuma S, Ogihara H, Kanekiyo S, Iida M, Sakamoto K, Suzuki N, et al. Metastatic ability and the epithelial-mesenchymal transition in induced cancer stem-like hepatoma cells. Cancer Sci. 2018;109(4):1101–9. doi:10.1111/cas.13527.
   PubMed Web of Science ®Google Scholar
• Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S. Cell-surface Vimentin: a mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer. 2015;137(2):491–496. doi:10.1002/ijc.29382.
   PubMed Web of Science ®Google Scholar
• Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri RK. Systems biology of cancer metastasis. Cell Syst. 2019;9(2):109–127. doi:10.1016/j.cels.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Jiang J, Ye F, Yang X, Zong C, Gao L, Yang Y, Zhao Q, Han Z, Wei L. Peri-tumor associated fibroblasts promote intrahepatic metastasis of hepatocellular carcinoma by recruiting cancer stem cells. Cancer Lett. 2017;404:19–28. doi:10.1016/j.canlet.2017.07.006.
   PubMed Web of Science ®Google Scholar
• Gasmi I, Machou C, Rodrigues A, Brouillet A, Nguyen TC, Rousseau B, Guillot A, Rodriguez C, Demontant V, Ait-Ahmed Y, et al. Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through miR-122 downregulation with increased risk of primary liver cancer initiation. Int J Biol Sci. 2022;18(5):1944–60. doi:10.7150/ijbs.70408.
   PubMed Web of Science ®Google Scholar
• Lai FB, Liu WT, Jing YY, Yu G-F, Han Z-P, Yang X, Zeng J-X, Zhang H-J, Shi R-Y, Li X-Y, et al. Lipopolysaccharide supports maintaining the stemness of CD133+ hepatoma cells through activation of the NF-κB/HIF-1α pathway. Cancer Lett. 2016;378(2):131–141. doi:10.1016/j.canlet.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology. 2014;147(6):1393–1404. doi:10.1053/j.gastro.2014.08.039.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang R, Xiong S, Wang X, Zhao Z, Bai S, Wang Y, Zhao Y, Cheng B. Cancer-associated fibroblasts promote the stemness of CD24(+) liver cells via paracrine signaling. J Mol Med (Berl). 2019;97(2):243–255. doi:10.1007/s00109-018-1731-9.
   PubMed Web of Science ®Google Scholar
• Mitra A, Yan J, Xia X, Zhou S, Chen J, Mishra L, Li S. IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta–deficient β2-spectrin+/− mice. Hepatology. 2017;65(4):1222–1236. doi:10.1002/hep.28951.
   PubMed Web of Science ®Google Scholar
• Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16(3):225–38. doi:10.1016/j.stem.2015.02.015.
   PubMed Web of Science ®Google Scholar
• Govaere O, Wouters J, Petz M, Vandewynckel Y-P, Van den Eynde K, Van den Broeck A, Verhulst S, Dollé L, Gremeaux L, Ceulemans A, et al. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. J Hepatol. 2016;64(3):609–17. doi:10.1016/j.jhep.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Cui CP, Wong CC, Kai AK, Ho DWH, Lau EYT, Tsui Y-M, Chan L-K, Cheung T-T, Chok KSH, Chan ACY, et al. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSumoylation and SENP1/HIF-1α positive feedback loop. Gut. 2017;66(12):2149–59. doi:10.1136/gutjnl-2016-313264.
   PubMed Web of Science ®Google Scholar
• Ling S, Shan Q, Zhan Q, Ye Q, Liu P, Xu S, He X, Ma J, Xiang J, Jiang G, et al. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation. Gut. 2020;69(7):1322–1334. doi:10.1136/gutjnl-2019-319616.
   PubMed Web of Science ®Google Scholar
• Won C, Kim BH, Yi EH, Choi K-J, Kim E-K, Jeong J-M, Lee J-H, Jang J-J, Yoon J-H, Jeong W-I, et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology. 2015;62(4):1160–73. doi:10.1002/hep.27968.
   PubMed Web of Science ®Google Scholar
• Govaert KM, Emmink BL, Nijkamp MW, Cheung ZJ, Steller EJA, Fatrai S, de Bruijn MT, Kranenburg O, Borel Rinkes IHM. Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells. Ann Surg. 2014;259(4):750–759. doi:10.1097/SLA.0b013e318295c160.
   PubMed Web of Science ®Google Scholar
• Wang X, Mao J, Zhou T, Chen X, Tu H, Ma J, Li Y, Ding Y, Yang Y, Wu H, et al. Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics. 2021;11(1):209–21. doi:10.7150/thno.49327.
   PubMed Web of Science ®Google Scholar
• Wei R, Zhu WW, Yu GY, Wang X, Gao C, Zhou X, Lin Z-F, Shao W-Q, Wang S-H, Lu M, et al. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. Int J Cancer. 2021;148(5):1233–44. doi:10.1002/ijc.33371.
   PubMed Web of Science ®Google Scholar
• Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, et al. Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. Hepatology. 2013;58(1):218–28. doi:10.1002/hep.26345.
   PubMed Web of Science ®Google Scholar
• Loh JJ, Li TW, Zhou L, Wong T-L, Liu X, Ma VWS, Lo C-M, Man K, Lee TK, Ning W, et al. FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness. Cancer Res. 2021;81(22):5692–705. doi:10.1158/0008-5472.CAN-20-4226.
   PubMed Web of Science ®Google Scholar
• Liu C, Liu L, Chen X, Cheng J, Zhang H, Zhang C, Shan J, Shen J, Qian C. LSD1 stimulates cancer-associated fibroblasts to drive Notch3-dependent self-renewal of liver cancer stem–like cells. Cancer Res. 2018;78(4):938–949. doi:10.1158/0008-5472.CAN-17-1236.
   PubMed Web of Science ®Google Scholar
• Wei Y, Shi D, Liang Z, Liu Y, Li Y, Xing Y, Liu W, Ai Z, Zhuang J, Chen X, et al. IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells. J Hepatol. 2019;71(6):1206–15. doi:10.1016/j.jhep.2019.08.034.
   PubMed Web of Science ®Google Scholar
• Kai F, Drain AP, Weaver VM. The extracellular matrix modulates the metastatic journey. Dev Cell. 2019;49(3):332–46. doi:10.1016/j.devcel.2019.03.026.
   PubMed Web of Science ®Google Scholar
• Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S, Benten D, Forbes SJ, Wells RG, Iredale JP, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology. 2011;53(4):1192–205. doi:10.1002/hep.24108.
   PubMed Web of Science ®Google Scholar
• Wang C, Jiang X, Huang B, Zhou W, Cui X, Zheng C, Liu F, Bi J, Zhang Y, Luo H, et al. Inhibition of matrix stiffness relating integrin β1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts. BMC Cancer. 2021;21(1):1276. doi:10.1186/s12885-021-08982-3.
   PubMed Web of Science ®Google Scholar
• Tian B, Luo Q, Ju Y, Song G. A soft matrix enhances the cancer stem cell phenotype of HCC cells. Int J Mol Sci. 2019;20(11):2831. doi:10.3390/ijms20112831.
   PubMed Web of Science ®Google Scholar
• Ng KY, Shea QT, Wong TL, Luk ST, Tong M, Lo C-M, Man K, Yun J-P, Guan X-Y, Lee TK, et al. Chemotherapy-enriched THBS2-deficient cancer stem cells drive hepatocarcinogenesis through matrix softness induced histone H3 modifications. Adv Sci (Weinh). 2021;8(5):2002483. doi:10.1002/advs.202002483.
   PubMedGoogle Scholar
• Wei J, Yao J, Yang C, Mao Y, Zhu D, Xie Y, Liu P, Yan M, Ren L, Lin Y, et al. Heterogeneous matrix stiffness regulates the cancer stem-like cell phenotype in hepatocellular carcinoma. J Transl Med. 2022;20(1):555. doi:10.1186/s12967-022-03778-w.
   PubMed Web of Science ®Google Scholar
• Li H, Sun Y, Li Q, Luo Q, Song G. Matrix stiffness potentiates stemness of liver cancer stem cells possibly via the Yes-Associated Protein Signal. ACS Biomater Sci Eng. 2022;8(2):598–609. doi:10.1021/acsbiomaterials.1c00558.
   PubMed Web of Science ®Google Scholar
• Zhao W, Lv M, Yang X, Zhou J, Xing B, Zhang Z. Liver tumor-initiating cells initiate the formation of a stiff cancer stem cell microenvironment niche by secreting LOX. Carcinogenesis. 2022;43(8):766–78. doi:10.1093/carcin/bgac035.
   PubMed Web of Science ®Google Scholar
• Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):404. doi:10.1038/s41392-021-00817-8.
   PubMed Web of Science ®Google Scholar
• Liu T, Xu H, Huang M, Ma W, Saxena D, Lustig RA, Alonso-Basanta M, Zhang Z, O’Rourke DM, Zhang L, et al. Circulating Glioma Cells Exhibit Stem Cell-like Properties. Cancer Res. 2018;78(23):6632–42. doi:10.1158/0008-5472.CAN-18-0650.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288(1):99–106. doi:10.1016/j.canlet.2009.06.027.
   PubMed Web of Science ®Google Scholar
• Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, Charafe-Jauffret E, Pham K, Molck C, Rolland N, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017;66(10):1802–10. doi:10.1136/gutjnl-2016-311447.
   PubMed Web of Science ®Google Scholar
• Wan S, Kim TH, Smith KJ, Delaney R, Park G-S, Guo H, Lin E, Plegue T, Kuo N, Steffes J, et al. New labyrinth microfluidic device detects circulating tumor cells expressing cancer stem cell Marker and circulating tumor microemboli in hepatocellular carcinoma. Sci Rep. 2019;9(1):18575. doi:10.1038/s41598-019-54960-y.
   PubMedGoogle Scholar
• Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013;133(9):2165–2171. doi:10.1002/ijc.28230.
   PubMed Web of Science ®Google Scholar
• Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng H-R, Lu SC, Yang JD. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422–436. doi:10.1002/hep.31165.
   PubMed Web of Science ®Google Scholar
• Nio K, Yamashita T, Okada H, Kondo M, Hayashi T, Hara Y, Nomura Y, Zeng SS, Yoshida M, Hayashi T, et al. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma. J Hepatol. 2015;63(5):1164–1172. doi:10.1016/j.jhep.2015.06.009.
   PubMed Web of Science ®Google Scholar
• Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu S-J, Shi R-Y, Hu B, Zhou J, Fan J, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57(4):1458–68. doi:10.1002/hep.26151.
   PubMed Web of Science ®Google Scholar
• Yang ZF, Ngai P, Ho DW, Yu WC, Ng MNP, Lau CK, Li MLY, Tam KH, Lam CT, Poon RTP, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47(3):919–28. doi:10.1002/hep.22082.
   PubMed Web of Science ®Google Scholar
• Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg. 2011;254(4):569–76. doi:10.1097/SLA.0b013e3182300a1d.
   PubMed Web of Science ®Google Scholar
• Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, Wang J, Zhang D, Cheng S, Liu S, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 2013;144(5):1031–1041.e10. doi:10.1053/j.gastro.2013.01.046.
   PubMed Web of Science ®Google Scholar
• Guo W, Sun YF, Shen MN, Ma X-L, Wu J, Zhang C-Y, Zhou Y, Xu Y, Hu B, Zhang M, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res. 2018;24(9):2203–13. doi:10.1158/1078-0432.CCR-17-1753.
   PubMed Web of Science ®Google Scholar
• Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, de Stanchina E, Massagué J. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016;165(1):45–60. doi:10.1016/j.cell.2016.02.025.
   PubMed Web of Science ®Google Scholar
• Maccalli C, Rasul KI, Elawad M, Ferrone S. The role of cancer stem cells in the modulation of anti-tumor immune responses. Semin Cancer Biol. 2018;53:189–200. doi:10.1016/j.semcancer.2018.09.006.
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120(9):3326–39. doi:10.1172/JCI42550.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang L, Chen J, Li C, Sun H, Wang J, Xiao H. Activation of tyrosine metabolism in CD13+ cancer stem cells drives relapse in hepatocellular carcinoma. Cancer Res Treat. 2020;52(2):604–621. doi:10.4143/crt.2019.444.
   PubMed Web of Science ®Google Scholar
• Nguyen PHD, Wasser M, Tan CT, Lim CJ, Lai HLH, Seow JJW, DasGupta R, Phua CZJ, Ma S, Yang J, et al. Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nat Commun. 2022;13(1):1441. doi:10.1038/s41467-022-29122-w.
   PubMed Web of Science ®Google Scholar
• Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14(3):155–167. doi:10.1038/nrclinonc.2016.144.
   PubMed Web of Science ®Google Scholar
• Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21(8):526–536. doi:10.1038/s41568-021-00366-w.
   PubMed Web of Science ®Google Scholar
• Hsu JM, Xia W, Hsu YH, Chan L-C, Yu W-H, Cha J-H, Chen C-T, Liao H-W, Kuo C-W, Khoo K-H, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9(1):1908. doi:10.1038/s41467-018-04313-6.
   PubMedGoogle Scholar
• Sung PS, Jang JW. Natural killer cell dysfunction in hepatocellular carcinoma: Pathogenesis and clinical implications. Int J Mol Sci. 2018;19(11):3648. doi:10.3390/ijms19113648.
   PubMed Web of Science ®Google Scholar
• Park DJ, Sung PS, Kim JH, Lee GW, Jang JW, Jung ES, Bae SH, Choi JY, Yoon SK. EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020;8(1):e000301. doi:10.1136/jitc-2019-000301.
   PubMed Web of Science ®Google Scholar
• Lo Re O, Mazza T, Giallongo S, Sanna P, Rappa F, Vinh Luong T, Li Volti G, Drovakova A, Roskams T, Van Haele M, et al. Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+regulatory T cells activation. Theranostics. 2020;10(2):910–924. doi:10.7150/thno.35045.
   PubMed Web of Science ®Google Scholar
• Wei Q, Qian Y, Yu J, Wong CC. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications. Oncogene. 2020;39(39):6139–56. doi:10.1038/s41388-020-01432-7.
   PubMed Web of Science ®Google Scholar
• Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80. doi:10.1038/s41568-021-00378-6.
   PubMed Web of Science ®Google Scholar
• Xie Y, Ma S, Tong M. Metabolic plasticity of cancer stem cells in response to microenvironmental cues. Cancers (Basel). 2022;14(21):5345. doi:10.3390/cancers14215345.
   PubMed Web of Science ®Google Scholar
• Wong TL, Che N, Ma S. Reprogramming of central carbon metabolism in cancer stem cells. Biochim Biophys Acta Mol Basis Dis. 2017;1863(7):1728–1738. doi:10.1016/j.bbadis.2017.05.012.
   PubMed Web of Science ®Google Scholar
• Fekir K, Dubois-Pot-Schneider H, Desert R, Daniel Y, Glaise D, Rauch C, Morel F, Fromenty B, Musso O, Cabillic F, et al. Retrodifferentiation of human tumor hepatocytes to Stem Cells Leads to Metabolic Reprogramming and Chemoresistance. Cancer Res. 2019;79(8):1869–83. doi:10.1158/0008-5472.CAN-18-2110.
   PubMed Web of Science ®Google Scholar
• Wei Z, Jia J, Heng G, Xu H, Shan J, Wang G, Liu C, Xia J, Zhou H, Wu M, et al. Sirtuin-1/Mitochondrial ribosomal protein S5 axis enhances the metabolic flexibility of liver cancer stem cells. Hepatology. 2019;70(4):1197–213. doi:10.1002/hep.30622.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. doi:10.1126/science.1160809.
   PubMed Web of Science ®Google Scholar
• Chen YY, Wang WH, Che L, Lan Y, Zhang L-Y, Zhan D-L, Huang Z-Y, Lin Z-N, Lin Y-C. BNIP3L-Dependent mitophagy promotes HBx-induced cancer stemness of hepatocellular carcinoma cells via glycolysis metabolism reprogramming. Cancers (Basel). 2020;12(3):655. doi:10.3390/cancers12030655.
   PubMed Web of Science ®Google Scholar
• Bi L, Ren Y, Feng M, Meng P, Wang Q, Chen W, Jiao Q, Wang Y, Du L, Zhou F, et al. HDAC11 regulates Glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. Cancer Res. 2021;81(8):2015–28. doi:10.1158/0008-5472.CAN-20-3044.
   PubMed Web of Science ®Google Scholar
• Gu Y, Ji F, Liu N, Zhao Y, Wei X, Hu S, Jia W, Wang XW, Budhu A, Ji J, et al. Loss of miR-192-5p initiates a hyperglycolysis and stemness positive feedback in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):268. doi:10.1186/s13046-020-01785-7.
   PubMed Web of Science ®Google Scholar
• Liu G, Luo Q, Li H, Liu Q, Ju Y, Song G. Increased oxidative phosphorylation is required for stemness maintenance in liver cancer stem cells from hepatocellular carcinoma cell line HCCLM3 cells. Int J Mol Sci. 2020;21(15):5276. doi:10.3390/ijms21155276.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Wang MD, Zhou X, Qin C-J, Fu G-B, Tang L, Wu H, Huang S, Zhao L-H, Zeng M, et al. Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment. Cancer Lett. 2017;388:1–11. doi:10.1016/j.canlet.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Lee ACK, Lau PM, Kwan YW, Kong SK. Mitochondrial fuel dependence on glutamine drives chemo-resistance in the cancer stem cells of hepatocellular carcinoma. Int J Mol Sci. 2021;22(7):3315. doi:10.3390/ijms22073315.
   PubMed Web of Science ®Google Scholar
• Li B, Cao Y, Meng G, Qian L, Xu T, Yan C, Luo O, Wang S, Wei J, Ding Y, et al. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2019;39:239–54. doi:10.1016/j.ebiom.2018.11.063.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Chen P, Yan HX, Fu G-B, Luo F-F, Zhang J, Zhao S-M, Zhai B, Yu J-H, Chen L, et al. Targeting mTORC2/HDAC3 inhibits stemness of liver cancer cells against glutamine starvation. Adv Sci (Weinh). 2022;9(20):e2103887. doi:10.1002/advs.202103887.
   PubMedGoogle Scholar
• Ye P, Chi X, Yan X, Wu F, Liang Z, Yang WH. Alanine–glyoxylate aminotransferase sustains cancer stemness properties through the Upregulation of SOX2 and OCT4 in hepatocellular carcinoma cells. Biomolecules. 2022;12(5):668. doi:10.3390/biom12050668.
   PubMed Web of Science ®Google Scholar
• Li H, Feng Z, He ML. Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells. Theranostics. 2020;10(16):7053–69. doi:10.7150/thno.41388.
   PubMed Web of Science ®Google Scholar
• Chen CL, Uthaya Kumar DB, Punj V, Xu J, Sher L, Tahara S, Hess S, Machida K. NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab. 2016;23(1):206–219. doi:10.1016/j.cmet.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Li H, Song J, He Y, Liu Y, Liu Z, Sun W, Hu W, Lei Q-Y, Hu X, Chen Z, et al. CRISPR/Cas9 screens reveal that Hexokinase 2 enhances cancer stemness and Tumorigenicity by activating the ACSL4-fatty acid β -oxidation pathway. Adv Sci (Weinh). 2022;9(21):e2105126. doi:10.1002/advs.202105126.
   PubMedGoogle Scholar
• Gagliardi F, Narayanan A, Gallotti AL, Pieri V, Mazzoleni S, Cominelli M, Rezzola S, Corsini M, Brugnara G, Altabella L, et al. Enhanced SPARCL1 expression in cancer stem cells improves preclinical modeling of glioblastoma by promoting both tumor infiltration and angiogenesis. Neurobiol Dis. 2020;134:104705. doi:10.1016/j.nbd.2019.104705.
   PubMed Web of Science ®Google Scholar
• Krishnapriya S, Sidhanth C, Manasa P, Sneha S, Bindhya S, Nagare RP, Ramachandran B, Vishwanathan P, Murhekar K, Shirley S, et al. Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. Angiogenesis. 2019;22(3):441–55. doi:10.1007/s10456-019-09669-x.
   PubMed Web of Science ®Google Scholar
• Li L, Li JC, Yang H, Zhang X, Liu L-L, Li Y, Zeng T-T, Zhu Y-H, Li X-D, Li Y, et al. Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis. Proc Natl Acad Sci U S A. 2018;115(38):E8948–E57. doi:10.1073/pnas.1806219115.
   PubMed Web of Science ®Google Scholar
• Tang W, Yu F, Yao H, Cui X, Jiao Y, Lin L, Chen J, Yin D, Song E, Liu Q, et al. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene. 2014;33(20):2629–38. doi:10.1038/onc.2013.214.
   PubMed Web of Science ®Google Scholar
• Yang XR, Xu Y, Yu B, Zhou J, Qiu S-J, Shi G-M, Zhang B-H, Wu W-Z, Shi Y-H, Wu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59(7):953–62. doi:10.1136/gut.2008.176271.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Gao J, Li C, Xu X, Hu Y, Huang S. Reactive oxygen species induce endothelial differentiation of liver cancer stem-like sphere cells through the activation of Akt/IKK signaling pathway. Oxid Med Cell Longev. 2020;2020:1–11. doi:10.1155/2020/1621687.
   Web of Science ®Google Scholar
• Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, Dieli F, Manno M, Raccosta S, Mancone C, Tripodi M, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015;14(1):155. doi:10.1186/s12943-015-0426-x.
   PubMedGoogle Scholar
• Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To K-F, Lai PB, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55(3):807–820. doi:10.1002/hep.24739.
   PubMed Web of Science ®Google Scholar
• Liu HL, Tang HT, Yang HL, Deng T-T, Xu Y-P, Xu S-Q, Peng L, Wang Z, Fang Q, Kuang X-Y, et al. Oct4 Regulates the Transition of cancer Stem-Like Cells to tumor Endothelial-Like Cells in Human liver cancer. Front Cell Dev Biol. 2020;8:563316. doi:10.3389/fcell.2020.563316.
   PubMed Web of Science ®Google Scholar